Skip to content

Redlands Daily Facts

60°F
Monday, January 26th 2026

e-Edition

Trending:

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ImmunityBio, Inc. - Common Stock (NQ:IBRX)

6.500 +0.050 (+0.78%)
Streaming Delayed Price Updated: 12:31 PM EST, Jan 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about ImmunityBio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
$5 Stocks: NDRA, IBRX, MOVE, RVLY Drawing Attention Watch Now!
Via AB Newswire
News headline image
ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy
From ImmunityBio, Inc.
Via Business Wire
News headline image
ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA® in BCG-Unresponsive Papillary Bladder Cancer
From ImmunityBio, Inc.
Via Business Wire
News headline image
ImmunityBio Announces Durable Complete Response of 15 Months with a Chemotherapy-Free CD19 CAR-NK Cell Therapy in Waldenstrom Lymphoma
From ImmunityBio, Inc.
Via Business Wire
News headline image
ImmunityBio Advances First-Line BCG Naive NMIBC Program with Enrollment Exceeding Expectations and Positive Interim Analysis for ANKTIVA® Plus BCG
From ImmunityBio, Inc.
Via Business Wire
News headline image
ImmunityBio Reports Continued Execution and Sales Momentum With $113 Million of Preliminary Net Product Revenue—a 700% increase year-over-year
From ImmunityBio, Inc.
Via Business Wire
News headline image
MAGA SmallCaps Watchlist: ROLR, SURG, IBRX, BNAI, NDRA – January 2026 Focus
Via AB Newswire
Topics Derivatives
News headline image
The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era
Issued on behalf of Oncolytics Biotech Inc. 
From USA News Group
Via GlobeNewswire
News headline image
Saudi FDA Grants Accelerated Approval to ImmunityBio’s ANKTIVA® In Combination with Checkpoint Inhibitors for Metastatic Non-Small Cell Lung Cancer
From ImmunityBio
Via Business Wire
News headline image
Saudi FDA Grants Accelerated Approval to ImmunityBio’s ANKTIVA® for Non-Muscle Invasive Bladder Cancer with Carcinoma In-Situ
From ImmunityBio, Inc.
Via Business Wire
News headline image
ImmunityBio Announces Positive Results Demonstrating ANKTIVA® as a Lymphocyte Stimulating Agent in Combination With Checkpoint Inhibitors in Non-Small Cell Lung Cancer
From ImmunityBio, Inc.
Via Business Wire
News headline image
NantWorks and ImmunityBio Announce Inaugural U.S.-Saudi Biotech Alliance Summit to Advance Immunotherapy 2.0 and Global Health Security
From ImmunityBio, Inc.
Via Business Wire
News headline image
ImmunityBio Founder Dr. Patrick Soon-Shiong Recognized as One of “100 Most Influential People in Oncology in 2025”
From ImmunityBio, Inc.
Via Business Wire
News headline image
ANKTIVA® with BCG Demonstrates 96% Survival from Bladder Cancer at Three Years with Median Survival Not Yet Reached in BCG-Unresponsive High-Grade Papillary-Only Non-Muscle Invasive Bladder Cancer
From ImmunityBio, Inc.
Via Business Wire
News headline image
ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ—A First in Europe
From ImmunityBio
Via Business Wire
News headline image
New Survey Reveals Non-Muscle Invasive Bladder Cancer Patients Seek More Care Conversations
From ImmunityBio, Inc.
Via Business Wire
News headline image
Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024
From ImmunityBio, Inc.
Via Business Wire
News headline image
ImmunityBio’s ANKTIVA® Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy
From ImmunityBio, Inc.
Via Business Wire
News headline image
Initial Data Shows 100% Disease Control in 5 Out of 5 Patients With Recurrent Glioblastoma With Two Patients in Near Complete Response Treated With ImmunityBio’s ANKTIVA®, NK Cell Therapy Plus Optune Gio® Device
From ImmunityBio, Inc.
Via Business Wire
News headline image
ImmunityBio Announces Phase 2 Study of ANKTIVA® in Patients with Long COVID
From ImmunityBio, Inc.
Via Business Wire
News headline image
ImmunityBio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients with Chemotherapy-Free, First-In-Class CD19 CAR-NK Immunotherapy
From ImmunityBio, Inc.
Via Business Wire
News headline image
ImmunityBio Announces Houston’s Michael E. DeBakey VA Medical Center Is Among the First VA Hospitals to Administer ANKTIVA® to Bladder Cancer Patients
From ImmunityBio, Inc.
Via Business Wire
News headline image
ImmunityBio Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025, With Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-code
From ImmunityBio, Inc.
Via Business Wire
News headline image
ImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional Investors
From ImmunityBio, Inc.
Via Business Wire
News headline image
ImmunityBio Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code with Regulatory Updates
From ImmunityBio, Inc.
Via Business Wire
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers
Via Investor Brand Network
News headline image
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers
EQNX::TICKER_START (NYSE:CLDI),(NASDAQ:VRTX),(NASDAQ:IBRX),(NASDAQ:CRSP),(NASDAQ:CTMX) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
News headline image
UK MHRA Approves ImmunityBio’s ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
From ImmunityBio, Inc.
Via Business Wire
News headline image
ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer
From ImmunityBio, Inc.
Via Business Wire
News headline image
ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors
From ImmunityBio, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.